CRISPR Therapeutics AG — Director's Dealing 2016

Oct 18, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2016-10-18

Reporting Person: CAGNONI PABLO J (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to Buy)	$5.60	2025-11-04	Common Shares (93833)		Direct
Stock Options (Right to Buy)	$12.57	2025-12-08	Common Shares (40263)		Direct

Footnotes

F1: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter.

F2: This option was granted on August 19, 2016 with respect to 40,263 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on the date of election as a director, December 8, 2015.